ClinicalTrials.gg
WithdrawnNCT02552641Updated Aug 5, 2022

Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole

A Phase 4 interventional study of Food effect and Esomeprazole in Helicobacter Pylori Infection, sponsored by EMS. Withdrawn at 1 site in Brazil. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by EMS · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of the study is assess whether the various forms of triple regimen of administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and any independent mealtime) influence the rate of eradication of this bacterium.

Read the detailed description

Phase IV, open, randomized, prospective study.

  • Length of experience: 180 days.
  • 06 visits.
  • Evaluation of the efficacy of differences regimens of administration.
02

Conditions studied

  • Helicobacter Pylori Infection
03

In context

Lead sponsor

EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants of both sexes;
  • Age greater than or equal to 18 and less than or equal to 50 years;
  • Participant diagnosed with type dyspepsia epigastric pain carriers of Helicobacter pylori infection, according to the classification of ROME III;
  • Ability to understand and consent to participate in this clinical study, manifested by reading, understanding and signing of the (IC).

Exclusion criteria

Exclusion Criteria:

  • Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the investigator as a medical risk to participate in the clinical trial;
  • Any laboratory examination found that the investigator doctor considers a risk to the research participant for their participation in the clinical trial;
  • Known to the drug components used during the study;
  • Women in pregnancy or breastfeeding period;
  • Women in reproductive age who do not agree to use acceptable methods of (oral contraceptives, injectable contraceptive, IUD, hormonal implants, barrier methods, abstinence, hormonal patch and tubal ligation); except surgically sterile (bilateral oophorectomy or hysterectomy);
  • Participating in the research that has participated in clinical trial protocols in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be direct benefit to it;
  • Party that has some kinship to the second degree or bond with employees or employees of Sponsor and Research Center;
  • Patients with predominant symptoms of reflux or irritable bowel syndrome, warning symptoms, peptic ulcer history or previous surgery in the upper segment of the gastrointestinal tract;
  • Patients with prior treatment history of eradication of Helicobacter pylori;
  • Patients with kidney, liver or heart failure;
  • Patients with past or current history of alcohol abuse;
  • Patients with a history of use of antibiotics or bismuth in the 4 weeks prior to study entry, PPIs or H2 blockers, NSAIDs or aspirin in the last two weeks;
  • Patients whose endoscopy show changes except hyperemic gastritis, erosive gastritis den considering the maximum of 5 erosions in this location or hiatal hernia;
  • Patients whose ultrasonography show hepato-biliopancreatic changes except steatosis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Test 1

    Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily

    Other: Food effect · Drug: Esomeprazole · Drug: Amoxicillin · Drug: Clarythromycin

  • Experimental
    Test 2

    Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily

    Other: Food effect · Drug: Esomeprazole · Drug: Amoxicillin · Drug: Clarythromycin

  • Experimental
    Test 3

    Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses

    Other: Food effect · Drug: Esomeprazole · Drug: Amoxicillin · Drug: Clarythromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of H pylori eradication

    Time frame: 7 days

Secondary outcomes

  1. side effects in each of the forms of triple therapy administration and compare them

    Time frame: 7 days

07

Study locations

1 site
  • Universidade de São Paulo
    São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2015 (actual). Primary completion is estimated for Feb 2016, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 17, 2015
StartActual
Sep 2015
Primary completionEst.
Feb 2016
CompletionEst.
Sep 2016
Last update
Aug 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02552641
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Sep 17, 2015
Start date
Sep 2015
Primary completion
Feb 2016 (estimated)
Completion
Sep 2016 (estimated)
Last update
Aug 5, 2022

Study contacts

Decio Chinzon, Phd
principal investigator · University of Sao Paulo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion